1
|
Belcaro G, Dugall M, Luzzi R, Corsi M, Ledda A, Ricci A, Pellegrini L, Cesarone MR, Hosoi M, Errichi BM, Cornelli U, Cotellese R, Agus G, Feragalli B. Management of Varicose Veins and Chronic Venous Insufficiency in a Comparative Registry with Nine Venoactive Products in Comparison with Stockings. Int J Angiol 2016; 26:170-178. [PMID: 28804235 DOI: 10.1055/s-0036-1597756] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
The aim of this registry study was to compare products used to control symptoms of CVI. Endpoints of the study were microcirculation, effects on volume changes, and symptoms (analogue scale). Pycnogenol, venoruton, troxerutin, the complex diosmin-hesperidin, Antistax, Mirtoselect (bilberry), escin, and the combination Venoruton-Pycnogenol (VE-PY) were compared with compressions. No safety or tolerability problems were observed. At inclusion, measurements in the groups were comparable: 1,051 patients completed the registry. Best performers : Venoruton, Pycnogenol, and the combination VE-PY produced the best effects on skin flux. These products and the combination VE-PY better improved PO 2 and PCO 2 . The edema score was decreased more effectively with the combination and with Pycnogenol. Venoruton; Antistax also had good results. Considering volumetry, the best performers were the combination PY-VE and the two single products Venoruton and Pycnogenol. Antistax results for edema were also good. The best improvement in symptoms score were obtained with Pycnogenol and compression. A larger decrease in oxidative stress was observed with Pycnogenol, Venoruton, and with the VE-PY combination. Good effects of Antistax were also observed. Parestesias were lower with Pycnogenol and with Antistax. Considering the need for interventions, the best performers were Pycnogenol, VE-PY, and compression. The efficacy of Pycnogenol and the combination are competitive with stockings that do not have the same tolerability in warmer climates. A larger and more prolonged evaluation is suggested to evaluate cost-efficacy (and non-interference with drugs) of these products in the management of CVI. The registry is in progress; other products are in evaluation.
Collapse
Affiliation(s)
- G Belcaro
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M Dugall
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - R Luzzi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M Corsi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - A Ledda
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - A Ricci
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - L Pellegrini
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M R Cesarone
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - M Hosoi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - B M Errichi
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - U Cornelli
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - R Cotellese
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - G Agus
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| | - B Feragalli
- Irvine 3 Labs, Circulation Sciences, CH-PE University, Italy
| |
Collapse
|
2
|
Belcaro G. A Clinical Comparison of Pycnogenol, Antistax, and Stocking in Chronic Venous Insufficiency. Int J Angiol 2015; 24:268-74. [PMID: 26648668 DOI: 10.1055/s-0035-1556060] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
This 8-week registry study was a comparative evaluation of Pycnogenol (French Maritime Pine Bark extract; Horphag Research, Geneva) and Antistax (grape leaf extract [GLE, Boehringer Ingelheim, Germany]) in controlling symptoms of chronic venous insufficiency (CVI). "Standard management" for CVI is compression; a group of comparable subjects was monitored to evaluate the effects of stockings. The registry included 183 patients (166 completing). Supplementation with Antistax (two tablets of 360 mg/d) or Pycnogenol (100 mg/d) was used. The groups were comparable for age, symptoms, venous incompetence, and microcirculation (with increased capillary filtration and skin flux) at inclusion. At 8 weeks, the rate of swelling (p < 0.05) and skin flux decreased toward normal values; changes were more important with Pycnogenol (p < 0.05). Transcutaneous Po 2 was increased more with Pycnogenol (p < 0.05). Ankle circumference was decreased more (p < 0.05) with Pycnogenol. An analog scale quantified symptoms. At 8 weeks, pain and edema were decreased with Pycnogenol and elastic compression (p < 0.05) with prevalence for Pycnogenol (p < 0.05). Edema with Pycnogenol was decreased by 40%. Induration was reduced only in the Pycnogenol group (p < 0.05) with minimal variations in the other groups. Tolerability and compliance were optimal. Elastic compression was correctly used by 80% of the patients indicating that it may be more difficult to use, particularly in warmer days. Costs for Pycnogenol were lower (96; 3.3 Euros) in comparison with the other groups (132;1.4 Euros for GLE and 149; 2.2 Euros for compression).
Collapse
Affiliation(s)
- Gianni Belcaro
- Irvine3 Labs, Biomedical Sciences, Chieti-Pescara University, Italy
| |
Collapse
|